Hummingbird Bio raises $19M in Series B round
Click here to read full article from source
Singapore, Dec. 5 -- Hummingbird Bioscience, an innovative biotherapeutics company located in Singapore and US, has announced that it has raised $19 million in a Series B financing round.
The financing was co-led by Mirae Asset Venture Investment and GNTech Venture Capital. Existing investors, Heritas Capital and Seeds Capital, as well as new investors, Delian Capital; Mirae Asset Capital; DAValue-GiltEdge; HB Investment; Wooshin Venture Investment; and Kiwoom Investment-Shinhan Capital also participated in the round.
Proceeds from the financing will support the discovery of new disease targets, expanding Hummingbird Bioscience's pipeline of first and best-in-class antibody therapeutics, as well as fueling the work on the co-discovery p...
To read the full article or to get the complete feed from this publication, please Contact Us